Perspective Therapeutics, Inc. (CATX): Reports 3Q 2026 Results
Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results • Updated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile
How this was made
The 30-second read
Why it matters
The 8‑K provides the first public disclosure of cash resources and early trial efficacy, which can materially affect valuation.
Market read
Micro‑cap biotech with novel oncology pipeline; results may trigger short‑term price movement.
What to watch
Cash runway is sufficient only to 2028; future financing needs could pressure the share price.
Perspective Therapeutics reports Q3 2026 net loss of $32.4 million as R&D expense rises to $26.1 million; cash, equivalents and short-term investments about $202 million
The quarter shows no meaningful revenue (grant revenue of $20 thousand), a wider net loss ($32.4 million vs $26.0 million) driven by higher R&D, and a higher operating loss. Against this, the company reports about $202 million in cash, equivalents and short-term investments and states this is expected to fund planned milestones into 2028, and it reports clinical and regulatory progress (PSV359 Fast Track Designation, updated NET data).
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Grant revenue, three months ended Sept 30, 2026GAAP | $20K | – | – |
| Research and development expenses, three months ended Sept 30, 2026GAAP | $26.1M | – | – |
| General and administrative expenses, three months ended Sept 30, 2026GAAP | $8.3M | – | – |
| Total operating expenses, three months ended Sept 30, 2026GAAP | $34.34M | – | – |
| Operating loss, three months ended Sept 30, 2026GAAP | −$34.32M | – | – |
| Interest income, three months ended Sept 30, 2026GAAP | $2.04M | – | – |
| Interest and other expense, three months ended Sept 30, 2026GAAP | −$157K | – | – |
| Total non-operating income, net, three months ended Sept 30, 2026GAAP | $1.88M | – | – |
| Net loss, three months ended Sept 30, 2026GAAP | $32.4M | – | – |
| Basic and diluted loss per share, three months ended Sept 30, 2026GAAP | $(0.27) | – | – |
| Cash, cash equivalents and short-term investments, as of Sept 30, 2026other | approximately $202 million | – | – |
| Total assets, as of Sept 30, 2026GAAP | $365.7M | – | – |
| Total stockholders' equity, as of Sept 30, 2026GAAP | $294.7M | – | – |
Capital returns
- The filing reports no share repurchases and no dividends for the period.
- Weighted average shares used in computing net loss per share (basic and diluted): 120,748 thousand for the three months ended Sept 30, 2026, compared to 74,296 thousand for the same period in 2025, as printed.
What drove it
- Research and development expenses were $26.1 million for the three months ended Sept 30, 2026, compared to $20.3 million a year earlier. The filing does not state the reasons for the change.
- General and administrative expenses were $8.3 million, compared to $7.7 million a year earlier.
- Clinical activity reported in the period: bamzireotide navoxetan (VMT-α-NET) Cohort 4 closed for recruitment with 20 patients enrolled as of Oct 30, 2026; the meningioma cohort has two patients treated; lapemelanotide zapixetar (VMT01) monotherapy cohort has 12 patients treated as of Oct 30, 2026; PSV359 dose-finding study had 17 patients treated as of Sept 30, 2026.
- PSV359 received FDA Fast Track Designation in October 2026 for adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. In September 2026 the company entered a clinical trial collaboration and supply agreement with Merck.
- Manufacturing: the company expects construction at the Chicago metro site to be completed in early 2027.
Concerns
- The net loss widened to $32.4 million from $26.0 million a year earlier, and basic and diluted loss per share was $(0.27) against $(0.35) in the prior-year period, on a share count of 120,748 thousand against 74,296 thousand.
- Grant revenue was $20 thousand in the quarter, compared to $209 thousand a year earlier. The company reports no product revenue in the documents provided.
- Total operating expenses rose to $34,342 thousand from $28,070 thousand, and the operating loss rose to $(34,322) thousand from $(27,861) thousand.
- The company's own forward-looking statements list risks including that clinical trials may be more costly or take longer than anticipated, the company may change strategy, and it may not secure sufficient isotope access. The filing also lists risks to the sufficiency of cash resources for future operating expenses and capital expenditures.
What to watch
- End-of-Phase 2 meeting with the FDA for bamzireotide navoxetan (VMT-α-NET), targeted for 1Q 2027.
- Five patients treated since the lapemelanotide zapixetar (VMT01) monotherapy cohort reopened in 3Q 2026; they are expected to reach at least 24 weeks of follow-up by mid-2027.
- Next clinical update for PSV359, planned in 2027.
- Completion of construction at the Chicago metro site, expected in early 2027.
- Whether cash, cash equivalents and short-term investments continue to fund planned milestones into 2028, given the quarterly operating loss reported here.
- Enrollment in the meningioma cohort and the VMT01 monotherapy cohort, both of which remain open.
Balance sheet and cash flow
- Cash and cash equivalents: $41,042 thousand as of Sept 30, 2026, compared to $30,629 thousand as of Dec 31, 2025.
- Short-term investments: $160,653 thousand as of Sept 30, 2026, compared to $114,108 thousand as of Dec 31, 2025.
- Cash, cash equivalents and short-term investments: approximately $202 million as of Sept 30, 2026, compared to approximately $145 million as of Dec 31, 2025.
- Property and equipment, net: $117,919 thousand as of Sept 30, 2026, compared to $76,597 thousand as of Dec 31, 2025.
- Total liabilities: $71,002 thousand as of Sept 30, 2026, compared to $59,941 thousand as of Dec 31, 2025.
- Total assets: $365,682 thousand as of Sept 30, 2026, compared to $266,972 thousand as of Dec 31, 2025.
- Total stockholders' equity: $294,680 thousand as of Sept 30, 2026, compared to $207,031 thousand as of Dec 31, 2025.
- The company states its cash, cash equivalents and short-term investments are sufficient to fund current planned clinical milestones and operational investments into 2028.
- Operating cash flow, investing cash flow and free cash flow are not reported in the documents provided.
Analysis
Perspective Therapeutics reported a Q3 2026 net loss of $32.4 million, or $(0.27) per basic and diluted share, against a net loss of $26.0 million, or $(0.35), in the same quarter of 2025. Research and development expense rose to $26.1 million from $20.3 million, and general and administrative expense rose to $8.3 million from $7.7 million. Total operating expenses were $34,342 thousand against $28,070 thousand, and the operating loss was $(34,322) thousand against $(27,861) thousand. Grant revenue was $20 thousand, down from $209 thousand, and the filing reports no other revenue line. Non-operating income, net, was $1,880 thousand against $1,892 thousand, with interest income of $2,037 thousand against $1,957 thousand. The filing does not state why R&D expense increased.
The balance sheet shows total assets of $365,682 thousand at Sept 30, 2026, up from $266,972 thousand at Dec 31, 2025, and stockholders' equity of $294,680 thousand, up from $207,031 thousand. Property and equipment, net, rose to $117,919 thousand from $76,597 thousand. Cash, cash equivalents and short-term investments were approximately $202 million, compared with approximately $145 million at Dec 31, 2025. The company states this is expected to fund current planned clinical milestones and operational investments into 2028. Weighted average shares used in the loss-per-share calculation were 120,748 thousand, compared with 74,296 thousand a year earlier. The filing does not describe the financing or equity transactions behind this change, and it does not provide operating cash flow.
On the clinical side, the company reported updated data for bamzireotide navoxetan (VMT-α-NET) presented at ESMO 2026 and NANETS 2026, closure of Cohort 4 with 20 patients enrolled, and a targeted end-of-Phase 2 meeting with the FDA in 1Q 2027. For lapemelanotide zapixetar (VMT01), it cited durable disease control with longer follow-up at SITC and 12 patients treated in a monotherapy cohort. For PSV359, the FDA granted Fast Track Designation in October 2026 and a Merck collaboration and supply agreement was signed in September 2026. The company's own description of these items is positive, but the filing gives no revenue, reimbursement or partnership economics to set against the expense base.
The quarter therefore reads as a pre-commercial development update. The figures that deserve attention are the wider net loss, the rise in operating expenses, the decline in grant revenue, and the cash balance that the company says supports operations into 2028. The next reported data points are the FDA end-of-Phase 2 meeting in 1Q 2027, the Chicago construction completion in early 2027, and the next PSV359 clinical update in 2027. The filing gives no formal financial guidance for the coming periods.
Management, verbatim
We have presented clinical data that demonstrated the potential of delivering alpha radiation via our proprietary targeted oncology platform,
Thijs Spoor, Chief Executive Officer
Not in the filing
stated, not guessed- Company financial guidance for future periods (none provided in the filing).
- Prior-year and prior-quarter percentage changes for any metric (not printed).
- Prior-quarter (Q2 2026) figures for any income statement line (not printed in the filing).
- Year-to-date or nine-month figures for the income statement (not printed in the filing).
- Segment or product revenue breakdown (not reported; company reports no segments in the documents).
- Operating cash flow, investing cash flow and free cash flow for the period (not printed).
- Reasons for the change in R&D expense (not stated in the filing).
- Prior-year same-date comparatives for cash, cash equivalents and short-term investments (only Dec 31, 2025 comparatives are printed).
- Financing transactions behind the increase in weighted average shares (not described).
- Net loss per share in the release text is printed as $0.27 and $0.35 without the parenthesis used in the table; the table form $(0.27) is used here.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Perspective Therapeutics is a radiopharmaceutical developer focusing on alpha‑emitting isotopes for cancer treatment.
Ticker impact
Perspective Therapeutics filed an 8‑K reporting Q3 2026 results, including $202 M cash balance, net loss of $32.4 M and positive Phase 1/2a data for bamzireotide and lapemelanotide programs.
potential upside as the market prices in the cash runway and encouraging early trial signals
First‑time disclosure of cash position and trial updates; no prior public release of these specific numbers or data.
Market effects
Early positive data may boost sentiment in the radiopharmaceutical and broader biotech sector.
U.S. biotech investors likely to react.
Limited to investors tracking niche oncology pipelines.
Counterpoint
The data are still early‑stage; without Phase III results the stock may face volatility and downside if later trials disappoint.
Key entities
- companyPerspective Therapeutics, Inc.
Radiopharmaceutical developer (ticker CATX).
- companyMerck
Partner in a supply agreement for PSV359 combination studies.
